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Abstract The aim of this 6-month, prospective, multi-
center study of 398 children and adolescents with primary
headaches was to collect data on headache treatment in
neuropediatric departments. Treatments were compared
before and after consultation. Prior to consultation, the
acute treatments that had been prescribed most frequently
were paracetamol (82.2% of children) and non-steroidal
anti-inﬂammatory drugs treatment (53.5%); 10.3% had
received a prophylactic treatment. No differences in either
acute or prophylactic treatment with respect to headache
diagnosis were observed. After the neuropediatric
consultation, paracetamol was replaced by a non-steroidal
anti-inﬂammatory drug in about three-quarters of cases and
by triptan in about one-quarter of cases. The number of
children prescribed a prophylactic treatment nearly dou-
bled, whereas there was a 5-fold and 23-fold increase in
psychotherapy and relaxation training, respectively,
between pre-referral and referral. We conclude that speciﬁc
treatments were underused for primary headache.
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Introduction
Headache is a common problem among children and ado-
lescents. It restricts teenage quality of life [1] and is a
major cause of absence from school as well as an important
factor in health-related costs among adolescents [2]. The
number of population-based studies assessing the preva-
lence of pediatric headache is limited [3, 4]. Published
prevalence for primary headache disorders vary consider-
ably, within a prevalence range of 1.0–17.0% for migraine
and 0.9–72.3% for episodic tension-type headache [4].
Pediatric headache remains under-recognized, under-
diagnosed and under-treated. However, the acute and pro-
phylactic therapies commonly used for primary headache
in children and adolescents are the same as those used in
adults and show similar efﬁcacy. Over the last 15 years,
behavioral therapies, notably biofeedback, have become
established as useful alternatives to drugs. The efﬁcacy of
these treatments has been established both by controlled
studies and by long-term follow-up studies [5]. Accurate
early diagnoses, as well as comprehensive and effective
treatment, are essential to minimize the impact of head-
aches on a child’s quality of life. Such interventions may
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DOI 10.1007/s10194-009-0158-7prevent progression and lifelong consequences, including
the development of comorbidities.
The Ce ´leste study is the ﬁrst cross-sectional, epidemi-
ological, multicenter survey of primary headache in chil-
dren and adolescents conducted in France. The primary
objective of this study, reported in a previous paper [6],
was to provide data on features of primary headache in
French children and adolescents. Brieﬂy, the typical con-
sulting child had headache characteristics highly reminis-
cent of migraine. With regard to classiﬁcation of headache
diagnoses, according to the second edition of the Interna-
tional Classiﬁcation of Headache Disorders (ICHD-II) [7],
proposed by the International Headache Society, migraine
(categories 1.1–1.6 in the ICHD-II classiﬁcation) accoun-
ted for 79% of the diagnoses. For most of the diagnostic
categories, the consistency of the investigator’s diagnosis
with the ICHD-II criteria was good or excellent. A second
aim of the Ce ´leste study was to collect data on headache
treatment in neuropediatric departments. Treatments were
compared before and after consultation.
Methods
This was a cross-sectional epidemiological survey of pri-
mary headache in children conducted in 22 hospital neu-
ropediatric departments in France between November 2005
and May 2006.
Participating physicians
Investigators were recruited from the French Society for
Paediatric Neurology. Physicians were selected at random
from the membership list of this society and invited to
participate in the study until the required number of 25
centers was reached.
Patients
The study included children aged between 2 and 16 years
consulting a neuropediatric center for primary headache for
the ﬁrst time. Children already participating in a clinical
trial or other studies were excluded. Each investigator was
expected to include serially the ﬁrst 25 patients, fulﬁlling
the entry criteria and consulting at the center during a six-
month inclusion period.
Data collection
At the consultation, a detailed clinical examination was
performed. The investigators completed a questionnaire for
each patient providing information on the demographic
proﬁle of the child, the headache diagnosis assigned, the
clinical features of the headache, triggering factors, per-
sonal and familial medical history, and treatment. Treat-
ments were identiﬁed from a checklist by their commercial
name and categorized by pharmacological class into acute
headache treatments, prophylactic treatments and non-
pharmacological treatments. The investigator completed a
headache feature checklist, which allowed the headache
type to be classiﬁed a posteriori according to the ICHD-II
classiﬁcation proposed by the International Headache
Society [7]. Once this had been performed, treatment was
re-evaluated and a new prescription delivered where
appropriate.
Statistical analysis
The size of the target study sample was determined by
a priori power calculations to determine the frequency of
key variables with a precision of 5% when observed in
50% of the samples. These calculations yielded a target
sample size of 384 subjects. To take into account poten-
tially non-evaluable subjects, it was decided to include 500
children. It was estimated that 20 physicians would need to
include 25 children each, to include this number of patients
over a 6-month period. To take into account physicians
who would agree to participate but then not recruit patients,
25 investigators were considered necessary to achieve the
target sample size.
The presentation of the headache treatments is purely
descriptive. Inter-group comparisons between headache
types were performed with the v
2 test or Fisher’s exact test
as appropriate. All tests were two sided and a probability
level of P\0.05 was considered signiﬁcant. All data were
controlled, validated and analyzed centrally using SAS
software, version 8.2 (SAS Institute, Cary, CA, USA).
Ethics
The study was performed according to international and
French regulatory guidelines and current codes of good
epidemiological practice. Since patient care was not altered
by inclusion in the study, ethics committee approval was
not necessary. With respect to conﬁdentiality of patient
records, data handling for the study was authorized by the
Commission Nationale d’Informatique et des Liberte ´s’.
Results
Study population
Overall, 479 children were included in the study: 252 girls
(52.6%) and 227 boys (47.4%). The mean age of the study
population was 9.8 ± 3.1 years (median, 10 years; range,
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1232–10 years). Of these children, 88 presented with multiple
types of headache. The remaining 398 children who pre-
sented with a single type of headache represent the study
population for the analysis of treatments. In this group, the
three most frequent headache diagnoses were migraine
without aura (195 children; 50.4%), probable migraine (50
children; 12.9%) and migraine with aura (44 children;
11.4%). For the purposes of this analysis of treatments, the
remaining 98 children with other diagnoses were combined
into an ‘other headache’ group. For 11 children, no speciﬁc
diagnosis was provided.
Acute headache treatments
At the time of the consultation, acute headache treatments
were being prescribed to 376 children (94.5% of the sam-
ple). The type of treatment prescribed is presented by age
group in Table 1 and by headache diagnosis as assigned by
the physician in Table 2. The acute treatments most fre-
quently prescribed were paracetamol (82.2% of children)
and non-steroidal anti-inﬂammatory drugs (53.5%). Spe-
ciﬁc headache treatments were prescribed infrequently,
namely ergot alkaloids to 6 children (1.5%) and triptans
to 12 children (3.0%). No distinct patterns of prescribing
were observed with respect to age, although the youngest
children (younger than 9 years) were more frequently
untreated (10.7% of this age group). With respect to
headache diagnosis, ergot alkaloids and triptans were pre-
scribed more frequently to patients assigned a diagnosis of
migraine with or without aura by the physician.
Prophylactic treatments
A total of 41 children were receiving a prophylactic
treatment at the time of consultation (10.3%), principally
an ergot alkaloid or an antiserotonergic drug (Table 1).
Prophylactic treatments were given most frequently to
children assigned a diagnosis of migraine without aura
(Table 2). However, regardless of treatment, only a
minority of children were reported to gain beneﬁt in terms
of a reduction in the frequency of headaches of at least 50%
or a reduction in perceived pain intensity (Table 3). The
treatment was generally considered to be well tolerated.
Non-pharmacological treatment
At the time of consultation, nine children had participated
in psychotherapy and three in relaxation techniques, to
manage their headaches, for a mean duration of 17.6 ±
25.7 months (median, 18 months) and 2.0 ± 1.4 months
(median, 2 months), respectively. However, a reduction in
headache frequency of at least 50% was only reported for
one child using psychotherapy, and a reduction in headache
intensity by two children using psychotherapy and one
using relaxation techniques.
Re-evaluation of diagnosis and treatment
Following completion of the headache feature checklist,
the diagnosis was re-assigned a posteriori using the ICHD-
II classiﬁcation. Fully exploitable data were obtained for
313 children (78.6% of the sample). In general, a high
concordance was observed between the physician’s diag-
nosis and the ICHD-II classiﬁcation. These data have been
presented in extenso elsewhere [6]. For the three headache
diagnoses considered here, the concordance ranged from
85.4% for migraine without aura to 95.4% for migraine
with aura. The distribution of treatments prescribed at the
time of consultation among the three ICHD-II diagnostic
groups was similar to their distribution among the original
physician-assigned diagnoses (data not shown).
At the end of the consultation, headache medication
prescription was revised. With respect to acute headache
treatments, analgesic medication was stopped in all cases
and paracetamol stopped in three-quarters of the children
originally prescribed this treatment (Table 4). In 75.7% of
these children, a non-steroidal anti-inﬂammatory drug was
substituted, together with triptan in 24.3% of cases, or
medication was stopped altogether (22.2%). The number of
children prescribed triptan increased nearly sixfold, prin-
cipally due to initiation of treatment in children previously
prescribed a non-steroidal anti-inﬂammatory drug or par-
acetamol. In parallel, the number of children prescribed a
prophylactic treatment nearly doubled from 34 to 64. This
Table 1 Headache treatments according to age
\9 years 9–12 years [12 years Total
N = 150 N = 161 N = 87 N = 398
Acute headache treatments, n (%)
NSAIDS 66 (44.0) 99 (61.5) 48 (55.2) 213 (53.5)
Paracetamol 115 (76.7) 135 (83.9) 77 (88.5) 327 (82.2)
Ergot alkaloid 1 (0.70) 4 (2.5) 1 (1.2) 6 (1.5)
Triptan None 4 (2.5) 8 (9.2) 12 (3.0)
Analgesics 1 (0.7) 3 (1.9) 1 (1.2) 5 (1.3)
None 16 (10.7) 4 (2.5) 2 (2.3) 22 (5.5)
Prophylactic treatments, n (%)
Antiserotonergics 2 (1.3) 8 (5.0) 6 (6.9) 16 (4.0)
Tricyclics None 1 (0.6) None 1 (0.3)
Beta blockers None 1 (0.6) 1 (1.2) 2 (0.5)
Ca channel blockers 1 (0.7) 2 (1.2) 1 (1.2) 4 (1.0)
Ergot alkaloids 4 (2.7) 12 (7.5) 12 (13.8) 28 (7.0)
Antiepileptic drugs 1 (0.7) 1 (0.6) None 2 (0.5)
No prophylaxis 145 (96.7) 140 (87.0) 72 (82.8) 357 (89.7)
Categories are non-exclusive, since children could be prescribed more
than one treatment
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123increase was with regard to all classes of prophylactic
medication, with the exception of ergot alkaloids, which
were stopped in half the children prescribed these drugs
(Table 4). The most frequently prescribed class of pro-
phylactic treatment was antiserotonergic drugs, accounting
for 43.8% of all prescriptions. Likewise, prescription of
non-pharmacological treatments also increased markedly,
with psychotherapy being offered to 33 children compared
to 7 previously, relaxation techniques being proposed to 43
compared to 2, and biofeedback started in 8 children.
Discussion
This was the second part of the Ce ´leste study, the ﬁrst
cross-sectional, epidemiological, multicenter survey of
primary headache in children and adolescents, conducted in
France. The results presented in this article concentrated
speciﬁcally on the therapeutic management of primary
headache in children and adolescents, with a comparison
between pre-referral and referral conditions.
Both migraine and tension-type headache require a
comprehensive treatment plan, which may include acute
and preventive therapy. The American Academy of Neu-
rology recently reviewed the available evidence for both
acute and preventive migraine therapies in detail, either
behavioral or pharmaceutical, in a Practice Parameter [8].
Inchildrenofage6–12 years,bothparacetamolat15 mg/kg
per dose or the non-steroidal anti-inﬂammatory drug
ibuprofen at 7.5–10 mg/kg per dose, taken when needed,
are effective and well tolerated [9, 10]. For the acute
treatment of migraine in adolescents of age 12–17 years, in
addition to ibuprofen, sumatriptan nasal spray at doses of
5–20 mg is effective and well tolerated [11]. Triptans,
migraine-speciﬁc medications, may be added to the treat-
ment plan when children have a moderate-to-severe
migraine, when the response to ibuprofen is either
incomplete or ineffective. Management of tension-type
headaches involves the use of intermittent analgesics
coupled with behavior interventions such as stress manage-
ment.Bothparacetamolandnon-steroidalanti-inﬂammatory
drugs are effective ﬁrst-line therapy for episodic tension-type
Table 2 Headache treatments according to physician diagnosis
Probable migraine Migraine with aura Migraine without aura Other headaches Total
N = 50 N = 44 N = 195 N = 98 N = 387
Acute headache treatments, n (%)
NSAIDS 19 (38.0) 26 (59.1) 115 (59.0) 49 (50.0) 209 (54.0)
Paracetamol 40 (80.0) 39 (88.6) 162 (83.1) 80 (81.6) 321 (83.0)
Ergot alkaloid None 2 (4.6) 3 (1.5) 1 (1.0) 6 (1.6)
Triptan None 1 (2.3) 10 (5.1) 1 (1.0) 12 (3.1)
Analgesics 1 (2.0) 2 (4.6) 1 (0.5) 1 (1.0) 5 (1.3)
None 3 (6.0) 1 (2.3) 5 (2.6) 10 (10.2) 19 (4.9)
Prophylactic treatments, n (%)
Antiserotonergics 1 (2.0) None 12 (6.2) 2 (2.0) 15 (3.9)
Tricyclics None None None 1 (1.0) 1 (0.3)
Beta blockers None None 2 (1.0) None 2 (0.5)
Ca channel blockers None None 2 (1.0) 2 (2.0) 4 (1.0)
Ergot alkaloids 4 (8.0) 2 (4.6) 16 (8.2) 5 (5.1) 27 (7.0)
Antiepileptic drugs 1 (2.0) None None 1 (1.0) 2 (0.5)
No prophylaxis 45 (90.0) 42 (95.5) 170 (87.2) 91 (92.9) 348 (89.9)
Categories are non-exclusive, since children could be prescribed more than one treatment. Data on diagnosis were missing for 11 children
Table 3 Perceived efﬁcacy and tolerance of headache prophylaxis
Treatment class N Reduced frequency, n (%) Reduced pain, n (%) Well tolerated, n (%)
Antiserotonergics 16 5 (31.3) 3 (18.8) 7 (43.8)
Tricyclic 1 None None 1 (100.0)
Beta blocker 2 1 (50.0) None 1 (50.0)
Ca channel blocker 4 None None 1 (25.0)
Ergot alkaloid 28 7 (25.0) 7 (25.0) 18 (64.3)
Antiepileptic drug 2 None 1 (50.0) None
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123headache [12]. The clinical characteristics and treatment
options in cluster headache are globally similar to those of
adult patients [13].
In France, the French Health Agency (Haute Autorite ´ de
Sante ´, HAS) published clinical guidelines for the thera-
peutic management of migraines in adults and children.
These were distributed to each general practitioner (GP) in
October 2002 [14]. The HAS recommended ibuprofen
(7.5–10 mg/kg) as the mainstay drug for acute migraine
attacks in children aged 6 months or older [14]. If ibu-
profen proved ineffective, the HAS recommended the use
of ergot derivatives from the age of 10 years onward,
despite the absence of evidence of efﬁcacy [15, 16], and the
use of sumatriptan nasal spray from the age of 12 years
onwards. In France, sumatriptan nasal spray is the only
triptan approved for migraine treatment of children and
adolescents 12 years or older. In this context, it is aston-
ishing that paracetamol was largely preferred by GPs.
Moreover, paracetamol was unsatisfactory in the majority
of cases. Perhaps the most striking ﬁnding of our study was
the fact that there was globally no distinct pattern of
prescribing with respect to diagnosis. Paracetamol was the
leading acute treatment that was indistinctly used for
migraine, tension-type headache or other primary head-
aches. Speciﬁc antimigraine drugs were equally underused,
although ergot alkaloids and triptans were prescribed
slightly more frequently to patients assigned a diagnosis of
migraine with or without aura by their physician. Not
surprisingly, the acute treatment prescribed following the
consultation in the neuropediatric department was more
suited to the diagnosis and more in line with present rec-
ommendations, either by the HAS or the American Acad-
emy of Neurology, with a nearly sixfold increase in triptan
prescription.
The decision to initiate prophylactic therapy must take
into account the disability caused by the headache disorder.
There is currently, however, no consensus on when to
initiate preventive measures; but daily prophylactic therapy
is warranted in about 20–30% of young migraineurs [17].
Most authors consider three to four migraines per month as
the threshold for initiating prophylactic treatment in pedi-
atric patients. Prophylactic pharmacological treatment
should be also considered in chronic tension-type headache
if non-pharmacological management is inadequate.
Prophylactic pharmacological headache treatments can
be classiﬁed into antiepileptic medications, antidepressant
medications, antiserotonergic medications and antihyper-
tensive medications, including both beta blockers and
calcium-channel blockers. Around 10% of children were
prescribed a prophylactic therapy. There was slight dif-
ference with respect to diagnosis, the only exception being
migraine with aura. GPs largely favored ‘‘old’’ prophy-
lactic medications, with ergot alkaloids and serotonin
antagonists being the two classes of drug they most often
prescribed. Dihydroergotamine remains one of the drugs
prescribed most often for childhood migraine prophylaxis
in western European countries, such as France or Germany,
despite lack of any proof of its efﬁcacy. To our knowledge,
only one controlled study with dihydroergotamine drops
has been reported in a pediatric population, which found no
statistical difference between placebo and dihydroergota-
mine [18]. Oxetorone, pizotifen and cyproheptadine were
the serotonin antagonists prescribed by GPs. The Practice
Parameter stated in its conclusions that pizotifen did not
show efﬁcacy and was not recommended and that there
was insufﬁcient evidence to make any recommendations
concerning the use of cyproheptadine [8]. No study
regarding the use of oxetorone in children is available.
Nevertheless, the three drugs have been recommended by
the HAS, which stated at the same time that there was
actually no evidence of their efﬁcacy [14]. In this setting it
is not astonishing that the perceived efﬁcacy by the patients
was poor. Both serotonin antagonists and ergot alkaloids
reduced frequency of headache frequency in less than a
third of cases. Newer prophylactic drugs, such as antiepi-
leptic medications, were rarely prescribed by GPs. While
Table 4 Original and revised headache treatments
Original
treatment, n (%)
Revised
treatment, n (%)
Change
Acute headache treatments
NSAIDS 175 (55.9) 202 (64.5) 1.15
Paracetamol 260 (83.1) 66 (21.1) 0.25
Ergot alkaloid 5 (1.6) 3 (1.0) 0.60
Triptan 9 (2.9) 58 (18.5) 6.44
Analgesics 4 (1.3) None –
None 16 (5.1) 43 (13.7) 2.69
Prophylactic treatments
Antiserotonergics 13 (4.2) 28 (9.0) 2.15
Tricyclics 1 (0.3) 8 (2.6) 8.00
Beta blockers 1 (0.3) 5 (1.6) 5.00
Ca channel blockers 4 (1.3) 7 (2.2) 1.75
Ergot alkaloids 25 (8.0) 14 (4.5) 0.56
Antiepileptic drugs 2 (0.6) 2 (0.6) 1.00
No prophylaxis 279 (89.1) 249 (79.6) 0.89
Non-pharmacological treatments
Psychotherapy 7 (2.2) 33 (10.5) 4.71
Relaxation 2 (0.6) 43 (13.7) 21.50
Biofeedback None 8 (2.6) –
Data are presented for the 313 children for whom an ICHD-II head-
ache diagnosis could be assigned. Categories are non-exclusive, since
children could be prescribed more than one treatment. The ‘change’
column represents the ratio between the revised treatment and the
original treatment
J Headache Pain (2009) 10:447–453 451
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nearly doubled following the consultation in the neurope-
diatric department, it is surprising that neuropediatricians
also favored ‘‘old-fashioned’’ prophylactic medications.
Antiserotonergic drugs were used most often, whereas
newer ones such as antiepileptic medications, for which the
evidence base for efﬁcacy is considerably more solid, were
infrequently prescribed.
Behavioral headache treatments include relaxation
training, biofeedback training, cognitive-behavioral ther-
apy or combinations of these treatments [19]. The avail-
ability of these therapies is limited in France and this may
explain why few patients beneﬁted from nonpharmacologic
treatments at referral. Nevertheless, following the re-eval-
uation by a neuropediatrician, non-pharmacologic rather
than drug treatments accounted for much of the increase
in headache prevention therapy. Whereas there was a
nearly 2-fold increase in the prescription of prophylactic
medication, there was a 5-fold and a 23-fold increase for
both psychotherapy and relaxation training, respectively,
whereas biofeedback prescription increased from 0 to 8
patients, between pre-referral and referral. This may also
indicate that there is a lack of knowledge of the possibility
of these therapeutic options by GPs.
The reasons for our ﬁndings are difﬁcult to understand,
in view of scientiﬁc progress in the ﬁeld of headache and
the efforts made by professional societies to improve the
standard of treatment [20]. GPs seem reluctant to be
involved strongly or directly in the management of primary
headache, especially in children, and prefer to delegate
specialists to prescribe treatments that require a precise
diagnosis [21].
Conclusion
The present study is the ﬁrst cross-sectional, epidemio-
logical, multicenter survey of primary headache, in
children and adolescents, conducted in France. It has
provided some insight into the management of primary
headache in French children and adolescents by general
practitioners. Paracetamol is still widely prescribed
despite the availability of speciﬁc antimigraine drugs,
such as triptans. Based on the prevalence and epidemi-
ology of pediatric primary headaches, it is clear that
general practitioners play a key role in the successful
management of those patients who do not require spe-
cialized neurological treatment. More treatment should
be individualized using a stratiﬁed care regimen, and
general practitioners should be more vigilant to prevent
migraine progression to chronic daily headache. Such
improvement requires continuing education for general
practitioners.
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